Supplementary material

Supplementary Table 1. *Post-hoc* subgroup analysis of overall survival.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Subgroups | Deaths/No. of patients, 3-year OS | | | | *p* | HR | 95% CI | |
| NACT + RS | | PS | |
| FIGO stage | | | | | | | | |
| IB2 | 2/9 | 77.8% | 3/9 | 77.8% | 0.850 | 0.841 | 0.139 | 5.092 |
| IIA, IIB | 2/11 | 80.8% | 3/16 | 87.5% | 0.805 | 1.254 | 0.204 | 7.699 |
| Lymph node status | | | | | | | | |
| Negative | 0/13 | 100.0% | 2/18 | 100.0% | 0.350 | 0.028 | 0.000 | 9043.076 |
| Positive | 4/7 | 38.1% | 4/7 | 42.9% | 0.615 | 1.418 | 0.352 | 5.714 |
| Surgical approach | | | | | | | | |
| Open surgery | 1/9 | 88.9% | 3/12 | 91.7% | 0.888 | 2.037 | 0.389 | 10.679 |
| Laparoscopic surgery | 3/11 | 72.7% | 3/11 | 76.9% | 0.772 | 1.267 | 0.256 | 6.280 |
| Tumor size | | | | | | | | |
| 2–4 cm | 0/6 | 100.0% | 2/8 | 87.5% | 0.265 | 0.022 | 0.000 | 3239.875 |
| >4 cm | 3/13 | 76.9% | 3/12 | 83.3% | 0.825 | 1.200 | 0.237 | 6.077 |
| Histological differentiation | | | | | | | | |
| Moderately to well differentiated | 2/11 | 81.8% | 4/16 | 87.5% | 0.941 | 1.068 | 0.190 | 6.003 |
| Poor differentiated | 1/6 | 83.3% | 1/4 | 75.0% | 0.695 | 0.577 | 0.036 | 9.297 |

FIGO, International Federation of Gynaecology and Obstetrics; OS, overall survival; NACT + RS, neoadjuvant chemotherapy followed by radical surgery; PS, primary surgery; HR, hazard ratio; 95% CI, 95% confidence interval.

Supplementary Table 2. *Post-hoc* subgroup analysis of progression-free survival.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Subgroups | Events/No. of patients, 3-year PFS | | | | *p* | HR | 95% CI | |
| NACT + RS | | PS | |
| FIGO stage | | | | | | | | |
| IB2 | 2/9 | 77.8% | 3/9 | 77.8% | 0.768 | 0.764 | 0.127 | 4.579 |
| IIA, IIB | 4/11 | 63.6% | 4/16 | 81.3% | 0.413 | 1.784 | 0.439 | 7.252 |
| Lymph node status | | | | | | | | |
| Negative | 0/13 | 100.0% | 2/18 | 100.0% | 0.297 | 0.024 | 0.000 | 4686.028 |
| Positive | 6/7 | 14.3% | 5/7 | 28.6% | 0.462 | 1.565 | 0.469 | 5.221 |
| Surgical approach | | | | | | | | |
| Open surgery | 3/9 | 66.7% | 3/12 | 91.7% | 0.391 | 0.845 | 0.081 | 8.799 |
| Laparoscopic surgery | 3/11 | 72.7% | 4/13 | 69.2% | 0.940 | 0.944 | 0.211 | 4.223 |
| Tumor size | | | | | | | | |
| 2–4 cm | 0/6 | 100.0% | 3/8 | 75.0% | 0.148 | 0.021 | 0.000 | 290.813 |
| >4 cm | 5/13 | 61.5% | 3/12 | 83.3% | 0.378 | 1.890 | 0.449 | 7.962 |
| Histological differentiation | | | | | | | | |
| Moderately to well differentiated | 3/11 | 72.7% | 5/16 | 81.3% | 0.895 | 1.102 | 0.259 | 4.694 |
| Poor differentiated | 2/6 | 66.7% | 1/4 | 75.0% | 0.897 | 1.172 | 0.106 | 12.978 |

FIGO, International Federation of Gynaecology and Obstetrics; PFS, progression-free survival; NACT + RS, neoadjuvant chemotherapy followed by radical surgery; PS, primary surgery; HR, hazard ratio; 95% CI, 95% confidence interval.

Supplementary Table 3. Univariate and multivariate analysis of prognostic factors.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Variables | | No | Overall survival | | | | | | | | Progression-free survival | | | | | | | |
| Univariate analysis | | | | Multivariate analysis | | | | Univariate analysis | | | | Multivariate analysis | | | |
| HR | 95% CI | | *p* | HR | 95% CI | | *p* | HR | 95% CI | | *p* | HR | 95% CI | | *p* |
| Age | | | | | | | | | | | | | | | | | | |
|  | <45 | 20 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| ≥45 | 25 | 8.077 | 1.022 | 63.833 | 0.048\* | 1.867 | 0.159 | 21.857 | 0.619 | 5.294 | 1.171 | 23.937 | 0.030\* | 2.109 | 0.317 | 14.015 | 0.440 |
| Tumor size | | | | | | | | | | | | | | | | | | |
|  | <4 cm | 13 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| ≥4 cm | 32 | 0.993 | 0.257 | 3.841 | 0.992 | 1.780 | 0.232 | 13.661 | 0.579 | 0.952 | 0.293 | 3.094 | 0.935 | 2.348 | 0.382 | 14.431 | 0.357 |
| Treatments | | | | | | | | | | | | | | | | | | |
|  | PS | 25 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| NACT + RS | 20 | 1.021 | 0.286 | 3.647 | 0.974 | 1.259 | 0.203 | 7.819 | 0.804 | 1.225 | 0.410 | 3.656 | 0.716 | 1.781 | 0.414 | 7.659 | 0.438 |
| Surgical approach | | | | | | | | | | | | | | | | | | |
|  | Open surgery | 21 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Laparoscopic surgery | 24 | 1.754 | 0.478 | 6.445 | 0.397 | 1.264 | 0.206 | 7.749 | 0.800 | 1.185 | 0.395 | 3.554 | 0.762 | 1.470 | 0.302 | 7.164 | 0.633 |
| Lymph node status | | | | | | | | | | | | | | | | | | |
|  | Negative | 31 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Postive | 14 | 32.828 | 3.923 | 274.715 | 0.001\* | 10.155 | 0.887 | 116.297 | 0.062 | 58.206 | 7.020 | 482.602 | <0.001\* | 36.495 | 3.541 | 376.170 | 0.003\* |
| Parametrial involvement | | | | | | | | | | | | | | | | | | |
|  | Negative | 40 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Postive | 5 | 16.356 | 3.964 | 67.497 | <0.001\* | 13.692 | 0.850 | 220.617 | 0.065 | 13.681 | 4.055 | 46.155 | <0.001\* | 5.626 | 0.623 | 50.799 | 0.124 |
| LVSI | | | | | | | | | | | | | | | | | | |
|  | Negative | 36 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Postive | 9 | 4.990 | 1.242 | 20.054 | 0.024\* | 0.240 | 0.018 | 3.156 | 0.278 | 5.872 | 1.847 | 18.670 | 0.003\* | 0.327 | 0.046 | 2.324 | 0.264 |
| Stromal invasion | | | | | | | | | | | | | | | | | | |
|  | <2/3 | 27 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| ≥2/3 | 18 | 18.788 | 2.359 | 149.627 | 0.006\* | 8.741 | 0.905 | 84.474 | 0.061 | 7.090 | 1.937 | 25.951 | 0.003\* | 2.594 | 0.503 | 13.390 | 0.255 |

NACT + RS, neoadjuvant chemotherapy followed by radical surgery; PS, primary surgery; LVSI, lymphovascular space invasion; HR, hazard ratio; 95% CI, 95% confidence interval.